|S-4||registration statement||Mar 27, 2017||2.0 MB|
|425||other||Mar 8, 2017||109.0 KB|
|425||other||Mar 1, 2017||109.1 KB|
|8-K||current report||Feb 28, 2017||123.1 KB|
|10-K||annual report||Feb 23, 2017||780.8 KB|
|425||other||Feb 23, 2017||184.2 KB|
|8-K||current report||Feb 23, 2017||184.0 KB|
|425||other||Feb 21, 2017||392.1 KB|
|425||other||Feb 21, 2017||150.1 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 14, 2017||142.3 KB|
|4||jacobs, cindy||Jan 12, 2017||156.8 KB|
|4||bencich, john||Jan 12, 2017||154.9 KB|
|4||cormack, scott daniel||Jan 12, 2017||158.5 KB|
|8-K||current report||Jan 6, 2017||939.2 KB|
|425||other||Jan 6, 2017||970.8 KB|
|425||other||Jan 6, 2017||127.3 KB|
|8-K||current report||Jan 5, 2017||723.7 KB|
|425||other||Jan 5, 2017||723.8 KB|
|8-K||current report||Nov 17, 2016||121.1 KB|
|10-Q||quarterly report||Nov 10, 2016||500.8 KB|
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.